Voyager Therapeutics, Inc. (VYGR)

Market Cap	177.08M
Revenue (ttm)	66.96M
Net Income (ttm)	-84.69M
Shares Out	55.34M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	303,242
Open	3.200
Previous Close	3.200
Day's Range	3.165 - 3.280
52-Week Range	2.645 - 9.550
Beta	0.85
Analysts	Strong Buy
Price Target	14.33 (+347.81%)
Earnings Date	Aug 5, 2025

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 172
• Stock Exchange: NASDAQ
• Ticker Symbol: VYGR
• Website: https://www.voyagertherapeutics.com

Analyst Summary

According to 8 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price target is $14.33, which is an increase of 347.81% from the latest price.

Price Target

$14.33

(347.81% upside)

Analyst Consensus: Strong Buy